Cel-Sci (NYSEAMERICAN:CVM) Announces Earnings Results

Cel-Sci (NYSEAMERICAN:CVM) posted its quarterly earnings data on Friday. The company reported ($0.67) EPS for the quarter, FiscalAI reports.

Cel-Sci Stock Up 10.0%

Cel-Sci stock opened at $1.43 on Friday. The stock has a market cap of $12.14 million, a PE ratio of -0.15 and a beta of 0.70. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.35 and a current ratio of 1.39. Cel-Sci has a one year low of $0.89 and a one year high of $13.48. The stock has a fifty day moving average of $3.29 and a 200 day moving average of $4.92.

Institutional Trading of Cel-Sci

A number of hedge funds have recently bought and sold shares of the company. HighTower Advisors LLC bought a new position in Cel-Sci in the 4th quarter worth $53,000. HRT Financial LP bought a new position in Cel-Sci in the 4th quarter worth $60,000. XTX Topco Ltd bought a new position in Cel-Sci in the 4th quarter worth $66,000. US Bancorp DE bought a new position in Cel-Sci in the 3rd quarter worth $80,000. Finally, Renaissance Technologies LLC bought a new position in Cel-Sci in the 4th quarter worth $81,000. Hedge funds and other institutional investors own 12.08% of the company’s stock.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.